The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
tarenflurbil
An orally active synthetic enantiomer of flurbiprofen. Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. Tarenflurbil does not inhibit the enzyme cyclo-oxygenase. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | R-flurbiprofen | |
| |||
| US brand name: | | Flurizan | |
| |||
| Code names: | | E-7869 MPC-7869 | |
| |||
| Chemical structure: | | (R)-2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid | |
| |||
